Lunai Bioworks Files Suit Over Alleged Short Selling Fraud Impacting Investors

Lunai Bioworks Takes Action Against Alleged Short Selling Fraud

Lunai Bioworks, Inc. (Nasdaq: LNAI), a company specializing in AI-driven precision medicine and biodefense, has recently filed an amended complaint in the U.S. District Court for the District of Delaware. This substantial legal document names ten defendants, including three FINRA-registered broker-dealers, allegedly involved in a naked short selling scheme that significantly affected the company’s shares. The complaint reveals a staggering claim of over 29 million shares that failed to deliver, underscoring serious allegations of market manipulation.

The Allegations

The core of Lunai's complaint is rooted in the assertion that the named defendants engaged in illegal short selling practices that resulted in an unprecedented failure to deliver on approximately 81% of the Company's outstanding shares. The complaint cites a striking example from March 17, 2026, when trading volume surged to an astonishing 554 million shares - nearly 15.3 times the total number of shares Lunai had issued at that time. Furthermore, on this day, market analytics indicated that there were no shares available for borrowing, which is a standard requirement under the federal law known as Regulation SHO for short sale transactions.

Highlighting the extreme nature of these allegations, the annualized borrow rate shot up to 621.45%, a significant increase from the 49.5% just four days earlier. Such figures reflect a pattern of manipulation that, according to Lunai, could represent systemic failures and misconduct by those involved in the scheme.

The Company’s Statement

Jacob Frenkel, co-lead counsel at Dickinson Wright PLLC, expressed the gravity of this situation, stating, "The scale of this fraud is staggering—investors have suffered substantial losses. It's time for those responsible for naked short selling to be held accountable." David Weinstein, the CEO of Lunai Bioworks, echoed these sentiments, declaring this filing as significant progress in their endeavor to seek justice for shareholders and restore integrity.

Weinstein mentioned, "Our investigation has revealed failures to deliver that parallel over 80% of our outstanding shares, with trading volumes extending far beyond our issued shares. We are committed to pursuing full accountability, including treble damages under the federal racketeering statute. We will continue to identify additional participants in this illicit scheme as we investigate further."

Legal Grounds

The amended complaint outlines claims under several federal laws, including securities fraud under the Securities Exchange Act of 1934, market manipulation, and civil racketeering. Lunai is not only seeking compensatory damages but is also requesting a jury trial to ensure thorough examination of the issues raised. They demand injunctive relief, costs, and attorney fees while continuing to monitor trading activities both retrospectively and in real-time.

This unfolding case has the potential to set a precedent for investor rights and protections concerning illicit trading practices. Lunai Bioworks claims it will enhance transparency and bring forth those individuals and firms engaged in unlawful naked short selling, reinforcing its commitment to safeguarding its business and shareholder interests.

As of now, Lunai is tapping into extensive trading data as part of its ongoing investigation. The company has stated it anticipates further amendments to the complaint to include any additional participants deemed necessary as the investigation unfolds.

For those interested in reviewing the specifics of the First Amended Complaint, a copy is available on Dickinson Wright's official website. As the legal situation develops, the implications for both investors and the market at large will be closely observed.

About Lunai Bioworks

Headquartered in Sacramento, California, Lunai Bioworks, Inc. operates at the forefront of utilizing artificial intelligence for precision medicine and biodefense solutions. With patented innovations aimed at transforming complex biomedical data into actionable insights for the development of sophisticated therapeutics, Lunai is positioned to play a crucial role in advancing medical science and public health.

For further updates and developments regarding Lunai Bioworks and their ongoing legal actions, stay connected with industry news and reports.